Experimental leukemia drug made available for patients who have no other options

NCT ID NCT05738538

AVAILABLE Disease control Sponsor: Kura Oncology, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This program provides expanded access to the experimental drug ziftomenib for adults with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) that has specific genetic changes (KMT2A rearrangements or NPM1 mutations). It is for patients who have exhausted standard treatments and have no satisfactory alternatives. The drug is given alone and is only available in the United States.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ziftomenib
What this could lead to: If it works, this could provide a treatment option for people with hard-to-treat leukemias who have run out of standard therapies.
What could go wrong: This is an early-stage expanded access program, not a large clinical trial. The drug may not work for everyone and could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates